Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
The same trial that sent Summit up 272% sees the stock crash 36%.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
But sasanlimab's use looks set to remain narrow.
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
